

## Consultant Year-End Index

# Index to Major Subjects and Authors, Volume 27, January-December 1987

### MAJOR SUBJECTS:

- Abdomen**, pain, in children. Gartner JC Jr. 87 Oct 152.
- Acid-base equilibrium**, using the anion gap measurement clinically. Gabow PA. 87 April 119.
- Acquired immunodeficiency syndrome**, and patient confidentiality. Goldberg BA. 87 Oct 70.
- intra-abdominal complications (Part 1). Andriole DP, Gouge TH, Plante MC. 87 Jan 106.
- questions most frequently asked by physicians. Volberding PA. 87 March 49.
- treatment and staff protection (Part 2). Andriole DP, Gouge TH, Plante MC. 87 Feb 145.
- Aging**, antiluler treatment. Sloan RW. 87 Aug 59.
- exercise for health and managing disease. South-Paul JE. 87 Feb 63.
- thyroid changes and their clinical implications. Felicetta JV. 87 Sept 71.
- Airway obstruction**, chronic, treatment. Kasik JE. 87 Nov 37.
- chronic, home oxygen therapy. Petty TL. 87 Dec 53.
- reversible, using inhaled  $\beta_2$ -bronchodilators as first-line therapy. Taylor RA, Speir WA. 87 April 134.
- Alcoholism**, how to spot it and what steps to take. Chappel JN. 87 April 60.
- Ankle joint**, knowing six basic mechanisms of injury speeds diagnosis. Wolin PM, D'Silva J, Buseck M. 87 Aug 130.
- Arrhythmia**, ventricular, approach to oral therapy. Meissner MD, Morganroth J. 87 Jan 32.
- Arthritis, rheumatoid**, systemic aspects. Hunder GG. 87 Nov 151.
- Arthroscopy**, of the knee, in osteoarthritis. Sequeira W, Arnold WJ. 87 Oct 25.
- Article Commentaries**
- AIDS: Pray for reason. Murphy DP. 87 Oct 3.
  - Choosing among the cephalosporins. Prichard JG, Rakel RE. 87 June 3.
  - Considering the atypical asthmatic patient. Shahady EJ. 87 Sept 3.
  - Contraceptive counseling: Helping patients keep the facts straight. Myers FW. 87 Nov 3.
  - Flexible fiberoptic sigmoidoscopy. Rozance C, Fitzgerald FT. 87 Aug 3.
  - Integrating old and new in antihypertensive therapy. Black HR. 87 April 3.
  - Look out America! Here comes cholesterol! Black HR. 87 Dec 3.
  - Promising therapy for migraine headache. Shahady EJ. 87 Jan 3.
  - Too much dogma, not enough science. Murphy DP. 87 July 3.
  - Upper GI endoscopy: too many? too few? too expensive? Farrar JT. 87 May 3.
- Asthma**, knowing which pulmonary function tests to use. Beer DJ. 87 July 29.

unusual presentations and causative mechanisms. Reynolds HY. 87 Sept 29.

**Asthma, exercise-induced**, testing methods and preventive measures. Owens GR. 87 March 23.

**Biopsy**, percutaneous, outpatient procedure guided by CT. Broderick TW. 87 June 142.

**Bites and stings**, mammalian, treatment. Heller MB. 87 Feb 40.

**Blood**, supplies, guarding against viral contamination. Chan JS, Vyas GN. 87 Oct 121.

**Blood substitutes**, redefined guidelines for children. Mahoney DH Jr. 87 Jan 130.

**Brief Consultations**

An awkward young athlete. Connolly JF. 87 Feb 115.

High hemoglobin levels—increased risk for stroke? Lerner RG. 87 May 39.

Indication for hyperlipidemia therapy. Thomas HE Jr. 87 Jan 82.

Insect bites and tetanus—when is prophylaxis necessary? McConnell RY. 87 Oct 43.

Lower testosterone in male distance runners. Northrop G. 87 Jan 147.

Make use of a valuable resource—the nutritionist. Lachance PA. 87 July 113.

Mammography—risk defined, accreditation on the way. Feig SA. 87 May 85.

Niacin therapy for hyperlipoproteinemia. Cressman MD, Hoogwerf BJ, Kohse LM. 87 Nov 57.

Nutritional needs, glucose intolerance in the elderly. Hazzard WR. 87 Nov 81.

Options when breast cancer risk is high. Carbone PP, Ravid PM. 87 Jan 41.

Possible candidate for radical keratotomy. Blodi FC. 87 March 40.

Pros and cons of fish oil. Levy RI. 87 Sept 56.

Saving the spleen. Engel S. 87 March 127.

Taking action on abnormal pap smears. Beaton JH, Newton M. 87 April 133.

The case of the restless legs. Bicknell JM. 87 Nov 117.

The importance of being a placebo— $\gamma$ -globulin and herpes. Redman JC. 87 June 40.

Toxicity of low-dose pulse methotrexate in the treatment of rheumatoid arthritis. Williams HJ. 87 June 151.

Tympanostomy tubes—to use or not to use. Harrison CJ. 87 March 143.

Unilateral eyelid twitch. Raskind R. 87 May 58.

Workplace programs for managing stress. Rosch PJ. 87 March 110.

**Burns**, minor, outpatient management. Cone JB. 87 Oct 37.

**Bursitis**, local injection therapy. Heller MB. 87 Dec 107.

**Calcium metabolism disorders**, hypercalcemia in children with hematuria. Stapleton FB. 87 Aug 73.

**Capitation fee**, in IPA-HMOs, financial risks and ethical dilemmas. Berenson RA. 87 Sept 100.

**Cardiomyopathy, congestive**, inflammatory, biopsy and immunosuppression. O'Connell JB. 87 May 146.

**Cardiovascular diseases**, hyperlipoproteinemia, risk assessment and dietary management (Part 1). Jones PH, Gotto AM. 87 Nov 126.

hyperlipoproteinemia, recommendations for cholesterol-lowering drugs (Part 2).

Jones PH, Gotto AM. 87 Dec 31.

indications for hyperlipidemia therapy.

Thomas HE Jr. 87 Jan 82.

**Cephalosporins**, selecting from the three generations. Amin NM. 87 June 25.

**Cerebral ischemia, transient**, questions frequently asked by physicians. Paulson GW. 87 July 23.

**Child**, abdominal pain, recurrent. Gartner JC Jr. 87 Oct 152.

gastroenteritis. Kish WJ. 87 Sept 127.

hypercalcemia complicating hematuria.

Stapleton FB. 87 Aug 73.

refined guidelines for blood component therapy. Mahoney DH Jr. 87 Jan 130.

**Cholelithiasis**, chemical dissolution for stones. Bol RJ. 87 Sept 129.

**Contraception**, counseling. Curran DL, Campbell BF. 87 Nov 23.

**Cost Containment, Competition, Constraints**

a medical society's response to HMO encroachment. Fischer LA. 87 March 95.

**ADS** and patient confidentiality. Goldberg BA. 87 Oct 70.

countering marketing practices by HMOs. Buenafor M. 87 June 92.

don't be intimidated by third-party payor decisions. Goldberg BA. 87 May 81.

financial risks and ethical dilemmas of capitation in IPA-HMOs. Berenson RA. 87 Sept 100.

flexible fiberoptic sigmoidoscopy, logistics and economics of office use. Varma JR. 87 Aug 96.

'gatekeeper' role for primary care physicians. Powe NR. 87 June 86.

HCFAs agenda for Medicare in the future.

Roper WL. 87 Sept 94.

how not to lose private patients over employer biases. Olson DR. 87 May 75.

marketing your practice, how it can be ethical. Shahady EJ. 87 March 90.

medical costs crisis (Part 1). Schroeder SA. 87 March 68.

medical costs crisis, how to regain control (Part 2). Schroeder SA. 87 April 82.

Medicare HMOs. Gillick MR. 87 Dec 97.

office laboratory, boon or burden? Kroger JS. 87 May 70.

office laboratory equipment selection and cost analysis. Kroger JS. 87 July 71.

## Consultant Year-End Index

# Index to Major Subjects and Authors, Volume 27, January-December 1987

### MAJOR SUBJECTS:

- Abdomen**, pain, in children. Gartner JC Jr. 87 Oct 152.
- Acid-base equilibrium**, using the anion gap measurement clinically. Gabow PA. 87 April 119.
- Acquired immunodeficiency syndrome**, and patient confidentiality. Goldberg BA. 87 Oct 70.
- intra-abdominal complications (Part 1). Andriole DP, Gouge TH, Plante MC. 87 Jan 106.
- questions most frequently asked by physicians. Volberding PA. 87 March 49.
- treatment and staff protection (Part 2). Andriole DP, Gouge TH, Plante MC. 87 Feb 145.
- Aging**, antiluler treatment. Sloan RW. 87 Aug 59.
- exercise for health and managing disease. South-Paul JE. 87 Feb 63.
- thyroid changes and their clinical implications. Felicetta JV. 87 Sept 71.
- Airway obstruction**, chronic, treatment. Kasik JE. 87 Nov 37.
- chronic, home oxygen therapy. Petty TL. 87 Dec 53.
- reversible, using inhaled  $\beta_2$ -bronchodilators as first-line therapy. Taylor RA, Speir WA. 87 April 134.
- Alcoholism**, how to spot it and what steps to take. Chappel JN. 87 April 60.
- Ankle joint**, knowing six basic mechanisms of injury speeds diagnosis. Wolin PM, D'Silva J, Buseck M. 87 Aug 130.
- Arrhythmia**, ventricular, approach to oral therapy. Meissner MD, Morganroth J. 87 Jan 32.
- Arthritis, rheumatoid**, systemic aspects. Hunder GG. 87 Nov 151.
- Arthroscopy**, of the knee, in osteoarthritis. Sequeira W, Arnold WJ. 87 Oct 25.
- Article Commentaries**
- AIDS: Pray for reason. Murphy DP. 87 Oct 3.
  - Choosing among the cephalosporins. Prichard JG, Rakel RE. 87 June 3.
  - Considering the atypical asthmatic patient. Shahady EJ. 87 Sept 3.
  - Contraceptive counseling: Helping patients keep the facts straight. Myers FW. 87 Nov 3.
  - Flexible fiberoptic sigmoidoscopy. Rozance C, Fitzgerald FT. 87 Aug 3.
  - Integrating old and new in antihypertensive therapy. Black HR. 87 April 3.
  - Look out America! Here comes cholesterol! Black HR. 87 Dec 3.
  - Promising therapy for migraine headache. Shahady EJ. 87 Jan 3.
  - Too much dogma, not enough science. Murphy DP. 87 July 3.
  - Upper GI endoscopy: too many? too few? too expensive? Farrar JT. 87 May 3.
- Asthma**, knowing which pulmonary function tests to use. Beer DJ. 87 July 29.

unusual presentations and causative mechanisms. Reynolds HY. 87 Sept 29.

**Asthma, exercise-induced**, testing methods and preventive measures. Owens GR. 87 March 23.

**Biopsy**, percutaneous, outpatient procedure guided by CT. Broderick TW. 87 June 142.

**Bites and stings**, mammalian, treatment. Heller MB. 87 Feb 40.

**Blood**, supplies, guarding against viral contamination. Chan JS, Vyas GN. 87 Oct 121.

**Blood substitutes**, redefined guidelines for children. Mahoney DH Jr. 87 Jan 130.

**Brief Consultations**

An awkward young athlete. Connolly JF. 87 Feb 115.

High hemoglobin levels—increased risk for stroke? Lerner RG. 87 May 39.

Indication for hyperlipidemia therapy. Thomas HE Jr. 87 Jan 82.

Insect bites and tetanus—when is prophylaxis necessary? McConnell RY. 87 Oct 43.

Lower testosterone in male distance runners. Northrop G. 87 Jan 147.

Make use of a valuable resource—the nutritionist. Lachance PA. 87 July 113.

Mammography—risk defined, accreditation on the way. Feig SA. 87 May 85.

Niacin therapy for hyperlipoproteinemia. Cressman MD, Hoogwerf BJ, Kohse LM. 87 Nov 57.

Nutritional needs, glucose intolerance in the elderly. Hazzard WR. 87 Nov 81.

Options when breast cancer risk is high. Carbone PP, Ravid PM. 87 Jan 41.

Possible candidate for radical keratotomy. Blodi FC. 87 March 40.

Pros and cons of fish oil. Levy RI. 87 Sept 56.

Saving the spleen. Engel S. 87 March 127.

Taking action on abnormal pap smears. Beaton JH, Newton M. 87 April 133.

The case of the restless legs. Bicknell JM. 87 Nov 117.

The importance of being a placebo— $\gamma$ -globulin and herpes. Redman JC. 87 June 40.

Toxicity of low-dose pulse methotrexate in the treatment of rheumatoid arthritis. Williams HJ. 87 June 151.

Tympanostomy tubes—to use or not to use. Harrison CJ. 87 March 143.

Unilateral eyelid twitch. Raskind R. 87 May 58.

Workplace programs for managing stress. Rosch PJ. 87 March 110.

**Burns**, minor, outpatient management. Cone JB. 87 Oct 37.

**Bursitis**, local injection therapy. Heller MB. 87 Dec 107.

**Calcium metabolism disorders**, hypercalcemia in children with hematuria. Stapleton FB. 87 Aug 73.

**Capitation fee**, in IPA-HMOs, financial risks and ethical dilemmas. Berenson RA. 87 Sept 100.

**Cardiomyopathy, congestive**, inflammatory, biopsy and immunosuppression. O'Connell JB. 87 May 146.

**Cardiovascular diseases**, hyperlipoproteinemia, risk assessment and dietary management (Part 1). Jones PH, Gotto AM. 87 Nov 126.

hyperlipoproteinemia, recommendations for cholesterol-lowering drugs (Part 2).

Jones PH, Gotto AM. 87 Dec 31.

indications for hyperlipidemia therapy.

Thomas HE Jr. 87 Jan 82.

**Cephalosporins**, selecting from the three generations. Amin NM. 87 June 25.

**Cerebral ischemia, transient**, questions frequently asked by physicians. Paulson GW. 87 July 23.

**Child**, abdominal pain, recurrent. Gartner JC Jr. 87 Oct 152.

gastroenteritis. Kish WJ. 87 Sept 127.

hypercalcemia complicating hematuria.

Stapleton FB. 87 Aug 73.

refined guidelines for blood component therapy. Mahoney DH Jr. 87 Jan 130.

**Cholelithiasis**, chemical dissolution for stones. Bol RJ. 87 Sept 129.

**Contraception**, counseling. Curran DL, Campbell BF. 87 Nov 23.

**Cost Containment, Competition, Constraints**

a medical society's response to HMO encroachment. Fischer LA. 87 March 95.

**ADS** and patient confidentiality. Goldberg BA. 87 Oct 70.

countering marketing practices by HMOs. Buenafor M. 87 June 92.

don't be intimidated by third-party payor decisions. Goldberg BA. 87 May 81.

financial risks and ethical dilemmas of capitation in IPA-HMOs. Berenson RA. 87 Sept 100.

flexible fiberoptic sigmoidoscopy, logistics and economics of office use. Varma JR. 87 Aug 96.

'gatekeeper' role for primary care physicians. Powe NR. 87 June 86.

HCFAs agenda for Medicare in the future. Roper WL. 87 Sept 94.

how not to lose private patients over employer biases. Olson DR. 87 May 75.

marketing your practice, how it can be ethical. Shahady EJ. 87 March 90.

medical costs crisis (Part 1). Schroeder SA. 87 March 68.

medical costs crisis, how to regain control (Part 2). Schroeder SA. 87 April 82.

Medicare HMOs. Gillick MR. 87 Dec 97.

office laboratory, boon or burden? Kroger JS. 87 May 70.

office laboratory equipment selection and cost analysis. Kroger JS. 87 July 71.

## Year-End Index

### Guide to Major Subjects and Authors

- physician-controlled HMOs. Payson NC. 87 July 64.
- physician-executive: emerging subspecialty for younger doctors. Nash DB. 87 Nov 97.
- physician profiling, how it can be misleading. Horn SD. 87 Dec 86.
- preferred provider organizations. Ermann D. 87 April 102.
- prepaid group practice, obvious and hidden tradeoffs in leaving private practice. Barenholz L. 87 March 85.
- recognizing your own grief reaction to practice changes. Gates WH. 87 Aug 88.
- starting a specialized clinic, pros and cons. Alberts PS, Alberts MS, Alberts SL. 87 Oct 83.
- the case for fee-for-service HMOs. Podolsky G. 87 April 97.
- young physicians: factors that shape their professional lives. Collins MF. 87 Nov 86.
- Decubitus ulcer**, how to succeed with conservative therapy. Klein HW. 87 June 133.
- Diabetes mellitus**, and therapy for hypertension. Cherner R. 87 Feb 22.
- counseling to dispel common misconceptions. Raffel LJ, Rimoin DL. 87 Jan 23.
- switching treatment to biosynthetic human insulin. Krosnick A. 87 July 78.
- Diabetes mellitus, non-insulin-dependent**, nutrition can be your primary treatment. Anderson JW, Gustafson NJ. 87 May 40.
- Diagnosis**, taking clues from unconventional sources. Fitzgerald FT. 87 Sept 49.
- Diagnosis, laboratory**, selecting and interpreting tests for bleeding disorders. Davis RB. 87 May 111.
- Diagnostic imaging**, of hepatobiliary tract, newer techniques. Grant EG, White EM, Zeman RK. 87 March 30.
- Diarrhea**, travelers', strategies to prevent. Johnson PC, DuPont HL, Ericsson CD. 87 May 102.
- Drug therapy**,  $\beta$ -blockers for migraine prophylaxis. Shapiro B. 87 Jan 117.
- $\beta$ -blockers for cardiac conditions and hypertension. Vida DG. 87 March 128.
- inhaled  $\beta_2$  bronchodilators as first-line therapy for reversible airway obstruction. Taylor RA, Speir WA. 87 April 134.
- nitrates, clinical indications and rationale for employment (Part 1). Abrams J. 87 June 154.
- nitrates, guidelines for various delivery systems (Part 2). Abrams J. 87 July 100.
- selecting right diuretic for edematous patient. Puschett JB. 87 May 125.
- Drugs**, antihypertensives, including new diuretics,  $\beta$ -blockers, sympatholytics (Part 1). Cressman MD, Gifford RW. 87 April 29.
- antihypertensives, including calcium channel blockers and ACE inhibitors (Part 2). Cressman MD, Gifford RW. 87 May 28.
- cephalosporins, selecting from among the three generations. Amun NM. 87 June 25.
- Economic competition**, how not to lose private patients over employer biases. Olson DR. 87 May 75.
- marketing your practice ethically. Shahady EJ. 87 March 90.
- pros and cons of starting a specialized clinic. Alberts PS, Alberts MS, Alberts SL. 87 Oct 83.
- Economics, medical**, costs crisis (Part 1). Schroeder SA. 87 March 68.
- costs crisis, how to regain control (Part 2). Schroeder SA. 87 April 82.
- Edema**, selecting the right diuretic. Puschett JB. 87 May 125.
- Editorial opinion**, gate guardian: a role for the FP to resume? Turner RB. 87 Oct 92.
- the dilemma of therapeutic substitution. Holverson HE. 87 June 166.
- Electrocardiography**, identifying diagnostic pitfalls. Parker BM. 87 Aug 34.
- Esophagus**, rupture (Puzz Case). Kessler MR. 87 Jan 124. A patient with abdominal pain and hyperamylasemia (Puzz Case). O'Shea JS. 87 Dec 75.
- Fractures**, facial, evaluation. Adams GL. 87 Oct 101.
- Gastroenteritis**, pediatric, early reintroduction of feeding. Klish WJ. 87 Sept 127.
- Gastrointestinal diseases** hepatobiliary imaging, advantages of newer techniques. Grant EG, White EM, Zeman RK. 87 March 30.
- Grief**, reaction, physician's own in response to practice changes. Gates WH. 87 Aug 88.
- Group practice, prepaid**, obvious and hidden tradeoffs in leaving private practice. Barenholz L. 87 March 85.
- Health maintenance organizations**, a medical society's response to prepaid care encroachment. Fischer LA. 87 March 95.
- countering their marketing practices. Buenaflor M. 87 June 92.
- medicare HMOs. Gillick MR. 87 Dec 97.
- physician-controlled HMOs. Payson NC. 87 July 64.
- Hearing loss**, early office evaluation. Niparko JK, Kemink JL. 87 April 39.
- Heart**, identifying diagnostic pitfalls in electrocardiography. Parker BM. 87 Aug 34.
- inflammatory dilated cardiomyopathy, biopsy and immunosuppression. O'Connell JB. 87 May 146.
- noncardiac surgery for cardiac patients. Silver MD, Cheitlin MD. 87 Oct 139.
- post-MI management to avert psychological problems. Taylor CB. 87 June 45.
- ventricular arrhythmias, oral therapy. Meissner MD, Morganroth J. 87 Jan 32.
- Heart valve diseases**, primary mitral valve prolapse. Berger P, Plehn JF. 87 Sept 114.
- Hemorrhage, gastrointestinal**, acute, pinpointing the source and defining treatment. Pepperman MA. 87 June 61.
- Hemorrhagic diathesis**, selection and interpretation of laboratory tests. Davis RB. 87 May 111.
- Hyperlipoproteinemia**, recommendations for cholesterol-lowering drugs (Part 2). Jones PH, Gotto AM Jr. 87 Dec 31.
- risk assessment and dietary management (Part 1). Jones PH, Gotto AM Jr. 87 Nov 126.
- Hypertension**, resistant, what to look for when a good regimen fails. Goodman RP. 87 Sept 65.
- review of new diuretics,  $\beta$ -blockers, sympatholytics (Part 1). Cressman MD, Gifford RW. 87 April 29.
- review of calcium channel blockers and
- ACE inhibitors (Part 2). Cressman MD, Gifford RW. 87 May 28.
- tracking secondary causes. Featherston WE, Ram CVS. 87 Aug 109.
- therapy with  $\beta$ -blockers, choosing the best one. Vida DG. 87 March 128.
- treatment when the patient is also diabetic. Cherner R. 87 Feb 22.
- Infection**, unpredictable neurologic syndromes. Poser CM. 87 Jan 45.
- Injections, intra-articular**, for bursitis and tendinitis. Heller MB. 87 Dec 107.
- Insulin**, human, switching from other sources. Krosnick A. 87 July 78.
- Insurance, health, reimbursement**, don't be intimidated by third-party payor decisions. Goldberg BA. 87 May 81.
- Laboratories, office**, boon or burden? Kroger JS. 87 May 70.
- office equipment, selection and cost analysis. Kroger JS. 87 July 71.
- Managed care programs**, 'gatekeeper' role for primary care physicians. Powe NR. 87 June 86.
- Marketing of health services**, how it can be ethical. Shahady EJ. 87 March 90.
- how not to lose private patients over employer biases. 87 May 75.
- Memorable Moments** emergency medicine. Gleeson FG. 87 Feb 96.
- on call. Cook SP. 87 Jan 166.
- Migraine**, prophylaxis with  $\beta$ -blockers. Shapiro DB. 87 Jan 117.
- Mitral valve prolapse**, diagnostic criteria. Berger P, Plehn JF. 87 Sept 114.
- Nails**, abnormalities as signs of systemic disease. Kpea NT, Scher RK. 87 Aug 47.
- Neoplasms**, abdominal, complications of AIDS (Part 1). Andriole DP, Gouge TH, Plante MC. 87 Jan 106.
- abdominal, complications of AIDS, treatment (Part 2). Andriole DP, Gouge TH, Plante MC. 87 Feb 145.
- breast, options with high risk. Carbone PP, Ravdin PM. 87 Jan 41.
- gastric, clinical options learned from Japanese. Douglass HO Jr. 87 Feb 75.
- soft-tissue, evaluation of mass in extremities. Lange TA. 87 Nov 62.
- testicular, promoting self examination. Swanson DA. 87 April 142.
- Nitrates**, current indications and rationale for employment (Part 1). Abrams J. 87 June 154.
- guidelines for various delivery systems. Abrams J. 87 July 100.
- Nutrition**, primary treatment for NIDDM. Anderson JW, Gustafson NJ. 87 May 40.
- Osteoarthritis**, arthroscopy of the knee. Sequeira W, Arnold WJ. 87 Oct 25.
- Osteoporosis**, therapy that can make a difference. Walter RM Jr. 87 March 115.
- Oxygen inhalation therapy**, home, for lung disease. Petty TL. 87 Dec 53.
- Pain**, recurrent abdominal, in children. Gartner JC Jr. 87 Oct 152.
- Paranasal sinus diseases**, orbital and intracranial complications of infection. Blitzer A. 87 Feb 131.
- Peptic ulcer**, how to detect and heal lesions. Koch MJ. 87 May 21.
- treatment in the elderly. Sloan RW. 87 Aug 59.
- Pharyngitis**, coping with unconventional causes. Gleckman RA, Gantz N. 87 Jan 159.

**Brief Summary of Prescribing Information****AUGMENTIN® amoxicillin/clavulanic potassium**

**Indications and Usage:** AUGMENTIN® is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below.

**Lower Respiratory Infections caused by  $\beta$ -lactamase-producing strains of *Hemophilus influenzae* and *Branhamella catarrhalis*.**

**Otitis Media caused by  $\beta$ -lactamase-producing strains of *Branhamella catarrhalis* and *Hemophilus influenzae*.**

**Skin and Skin Structure Infections caused by  $\beta$ -lactamase-producing strains of *Staphylococcus aureus*, *E. coli*, and *Klebsiella* spp.**

**Urinary Tract Infections caused by  $\beta$ -lactamase-producing strains of *E. coli*.**

***Klebsiella* spp. and *Enterobacter* spp.**

While AUGMENTIN® is indicated for the conditions listed above infections caused by ampicillin susceptible organisms are also amenable to AUGMENTIN® treatment due to its amoxicillin content. Therefore, mixed infections caused by ampicillin susceptible organisms and  $\beta$ -lactamase-producing organisms susceptible to clavulanic acid should be treated with AUGMENTIN®.

**Bacteriologic studies to determine the causative organisms and their susceptibility to AUGMENTIN® should be performed together with any indicated surgical procedures.**

Testing may be instituted prior to obtaining the results from bacteriological and susceptibility studies to determine the causative organisms and their susceptibility to AUGMENTIN® when there is reason to believe the infections may involve any of the  $\beta$ -lactamase-producing organisms listed above. Once the results are available, therapy should be initiated as indicated by the results of the tests.

**Contraindications:** A history of allergic reactions to any penicillin is a contraindication.

**WARNINGS: SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN AND AMpicillin. THESE REACTIONS ARE FRIQUENTLY FOLLOWED BY PARENTERAL THERAPY. IT HAS OCCURRED IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND / OR A HISTORY OF SENSITIVITY TO OTHER PENICILLINS. THESE REACTIONS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS BEFORE INITIATING THERAPY WITH ANY PENICILLIN. CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY TO PENICILLIN AND CEPHALOSPORINS IN INDIVIDUALS TAKING PENICILLIN. IF AN ALLERGIC REACTION OCCURS, AUGMENTIN® SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE, OXYGEN, AIRWAY MANAGEMENT, AND CARDIOPULMONARY SUPPORT, INCLUDING INTUBATION. SHOULD ALSO BE ADMINISTERED AS INDICATED.**

**Precautions:** General: While AUGMENTIN® possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system function, including renal, hepatic and hematopoietic function is advisable during prolonged therapy.

A high percentage of patients with mononucleosis who receive ampicillin develop a skin rash. Thus, ampicillin class antibiotics should not be administered to patients with mononucleosis.

The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur, usually involving *Pseudomonas* or *Candida*, the drug should be discontinued and/or appropriate therapy should be initiated.

**Drug/Laboratory Test Interactions:** Oral administration of AUGMENTIN® will result in high urine concentrations of amoxicillin. High urine concentrations of amoxicillin may result in false positive reactions when testing for the presence of glucose in urine. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or Testape®) be used.

It has been reported that oral amoxicillin to pregnant women transient decrease in plasma concentrations of total conjugated estrogens, estradiol-glucuronide, conjugated estriol and estradiol has been noted. This effect may also occur with amoxicillin and therefore AUGMENTIN®. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or Testape®) be used.

It has been reported that oral amoxicillin to pregnant women transient decrease in plasma concentrations of total conjugated estrogens, estradiol-glucuronide, conjugated estriol and estradiol has been noted. This effect may also occur with amoxicillin and therefore AUGMENTIN®.

**Drug Interactions:** Probable decrease in the renal tubular secretion of amoxicillin. Consequently, AUGMENTIN® may result in increased and prolonged blood levels of amoxicillin.

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving either drug alone. It is not known whether this increase in ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. There are no data with AUGMENTIN® and allopurinol administered concurrently.

**Augmentin® should not be co-administered with Antabuse® (disulfiram).**

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential.

**Pregnancy (Category B):** Reproduction studies have been performed in mice and rats at doses up to 10 times the human dose and have revealed no evidence of teratogenicity or harm to the fetus due to AUGMENTIN®. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Lactation:** Data on lactation in humans are generally poorly absorbed during labor. Studies in quinea pigs have shown that intravenous administration of amoxicillin decreased the uterine tone, frequency of contractions, height of contractions and duration of contractions. However, it is not known whether the use of amoxicillin during lactation would have similar effects. It is not known if adverse effects on the fetus, prolongs the duration of labor or increases the likelihood that forces delivery after other obstetrical intervention or resuscitation of the newborn will be necessary.

**Nursing Mothers:** Ampicillin class antibiotics are excreted in the milk; therefore, caution should be exercised when AUGMENTIN® is administered to a nursing woman.

**Adverse Reactions:** AUGMENTIN® is generally well tolerated. The majority of side effects are believed to be drug related and a manifestation of the pharmacological action of amoxicillin. The most common adverse effects are diarrhea, nausea, vomiting, rash, urticaria, and vaginitis. The most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), vomiting (1%), skin rashes and urticaria (3%) and vaginitis (1%).

The overall incidence of side effects, and in particular diarrhea, increased with the dose of AUGMENTIN®. Other less frequently reported reactions include: abdominal discomfort, flatulence and headache.

The following adverse reactions have been reported for ampicillin class antibiotics:

**Gastrointestinal:** Diarrhea, nausea, vomiting, gastritis, stomatitis, glossitis, black hairy tongue, enterocolitis and pseudomembranous colitis.

**Hypersensitivity Reactions:** Skin rashes, urticaria, erythema multiforme and an occasional case of exfoliative dermatitis have been reported. These reactions may be considered drug related. Symmetric cutaneous eruptions, which in some cases react to the drug should be discontinued unless the opinion of the physician dictates otherwise. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions can occur with oral penicillin (See Warnings).

**Lymphatic:** A moderate rise in SGOT and/or SGPT has been noted in patients treated with ampicillin class antibiotics as well as with AUGMENTIN® but the significance of these findings is unknown.

**Hematologic Lymphatic Systems:** Anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, neutropenia and agranulocytosis have been reported during therapy with penicillin. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytopenia was noted in less than 1% of the patients receiving AUGMENTIN®.

**Deaths:** There have been one death due to one AUGMENTIN® 250 tablet every eight hours. For more severe infections and infections of the respiratory tract, the dose should be one AUGMENTIN® 500 tablet every eight hours.

Since two AUGMENTIN® 250 and 500 tablets contain the same amount of amoxicillin as one AUGMENTIN® 500 tablet, therefore two AUGMENTIN® 250 tablets should not be substituted for one AUGMENTIN® 500 tablet for treatment of more severe infections.

**Children:** The usual dose is 40 mg/kg/day on the amoxicillin component, in divided doses every eight hours. For otitis media, sinusitis and other more severe infections, the dose should be 40 mg/kg/day, based on the amoxicillin component, in divided doses every eight hours. Also available as AUGMENTIN® 125 and 250 chewable tablets.

**Children:** Children weighing 40 kg and more should be dosed according to the adult recommendations.

**Becham laboratories © 1987**

9417093/B86 Rev Dec 1986

## Year-End Index

Guide to  
Major Subjects  
and Authors

### Photoclinic

- 87 Jan 73. Keratosis punctata, Hailey-Hailey disease, segmental vitiligo, chronic radiation dermatitis, reactive perforated collagenosis
- 87 Feb 91. Raynaud's phenomenon, tinea corporis, neomycin contact dermatitis, lymphogranuloma venereum, secondary syphilis, keratitis pilaris
- 87 March 103. Erythropoietic protoporphyrin (EPP), Hirschsprung's disease, perirectal telangiectasia, North American blastomycosis, nephrotic syndrome, lymphedema tarda with cellulitis
- 87 April 111. Chronic osteomyelitis, nickel dermatitis, broncholiths
- 87 May 95. Pustular psoriasis (von Zumbusch), 'Puss' caterpillar sting, cavernous hemangioma, scalded skin syndrome, 'dyshidrotic' eczematous dermatitis

- 87 June 97. Allergic conjunctivitis, dermatofibroma, Cat-Scratch disease, procainamide reaction, Beau's lines
- 87 July 93. Impetigo contagiosa, bilateral adrenal hemorrhage, lumbosacral herpes simplex, granuloma annulare, Becker's nevus, panniculitis
- 87 Aug 105. Erythema elevatum diutinum, leiomyomas, erythema nodosum, scurvy, *Mycobacterium marinum* infection
- 87 Sept 107. Lymphocytic infiltration of the skin, myotonic dystrophy, 'cryptic' tonsil with exudate, eczema herpetiformis
- 87 Oct 95. Kaposi's sarcoma of the conjunctiva, pyogenic granuloma, incontinentia pigmenti, shoe dermatitis
- 87 Nov 119. Goiter in postpartum thyroiditis, elephantiasis nostras verrucosa, livedo reticularis, colon cancer, congenital diaphragmatic hernia, dysplastic nevi
- 87 Dec 103. Sweet's syndrome, chronic discoid lupus erythematosus (CDLE), tuberculoid leprosy (benign Hansen's disease), scrotal edema (nephrotic syndrome), Fox-Fordyce disease

**Physician incentive plans, the case for fee-for-service HMOs.** Podolsky G. 87 April 97.

### Practical Pointers

- A sling to remove a stuck ring. 87 Jan 31.
- Attention-getting helps the NG tube go down. 87 Aug 55.
- Ash-leaf lesions a clue. 87 May 93.
- Avoid problems with ET tube. 87 Oct 156.
- Breast exam—help your patients help themselves. 87 Dec 82.
- Bull's eye for lumbar puncture. 87 May 64.
- Caveats on urine dipstick test. 87 June 80.
- Clear the ear for treatment. 87 Nov 74.
- Clear the lesions, then shampoo the skin. 87 Nov 74.
- Computer speeds record retrieval. 87 Aug 84.
- Cool down inflammation the inexpensive way. 87 July 110.
- Counterstimulus eases venipuncture pain. 87 Aug 102.
- Curet first, then sound. 87 June 80.
- De-bugging the ear. 87 July 58.
- Detecting a foreign body. 87 April 76.
- Detecting sounds of a broken rib. 87 March 62.
- Device for colostomy irrigation. 87 March 62.

- Device to mix and mete medication. 87 Nov 74.
- Distraction from DPT shot pain. 87 Nov 74.
- Don't say 'ah'. 87 June 148.
- Dress the dressing. 87 Oct 54.
- Drying a pipette. 87 Sept 84.
- Ear-rigation backsplash protection. 87 May 64.
- Ease fears, build trust early. 87 Sept 84.
- Easing nasotracheal intubation. 87 April 76.
- Easing pain on the x-ray table. 87 April 116.
- Easing venipuncture with a bent needle. 87 July 58.
- Elbow exam for fracture. 87 June 80.
- Electronic refill requests. 87 March 62.
- Enhancing x-ray films. 87 July 110.
- Epidermal emollient. 87 July 58.
- Epistaxis stop-leak. 87 Nov 78.
- Fearless venipuncture. 87 March 122.
- Fishing for debris in the nose. 87 Feb 39.
- Flag glaucoma to avoid medication reactions. 87 June 80.
- Flexibility for ear exam. 87 Jan 129.
- Focus on radiographs. 87 Aug 84.
- Folic acid therapy and vitamin B<sub>12</sub> level. 87 March 62.
- Gastric bleeding. 87 March 122.
- Get history before giving I.V. asthma medication. 87 Oct 54.
- Getting cooperation for the pediatric throat exam. 87 Aug 84.
- Getting the picture across. 87 May 64.
- Giardia lamblia* and its sneaky tricks. 87 July 58.
- Glans irritation not necessarily VD. 87 Aug 58.
- Heart rate calculation simplified. 87 March 62.
- Hidden benefits from discharge sheets. 87 Nov 78.
- Improving palatability of skim milk. 87 April 116.
- Instant bedside test of heparin efficacy. 87 June 114.
- Intimate transfer of allergen. 87 March 154.
- Irritant-free deodorant. 87 May 93.
- Joint problems. 87 May 64.
- Light up your night. 87 Dec 82.
- Listen to lungs with a light assist. 87 May 46.
- Listening for carotid bruits. 87 Sept 80.
- Lithium-thyroid interaction. 87 June 148.
- Make sure it's a polyp. 87 Oct 54.
- Melenophobia. 87 May 46.
- Muscle spasm—diagnosis and relief in one step. 87 Aug 84.
- Nature knows best. 87 July 90.
- Neat solution to a grubby problem. 87 Sept 84.
- Nerve block for lip wounds. 87 July 58.
- Nourishment for weak patients. 87 July 88.
- Office audiometry for preschoolers. 87 Sept 80.
- Office treatment of abscesses. 87 Nov 74.
- One cause of unexplained paralysis. 87 April 108.
- One way to help make the bandage stick. 87 Sept 80.
- Pain-free circumcision. 87 April 116.
- Painless steering for arthritic agriculturists. 87 April 76.
- Pill-swallowing maneuver. 87 Oct 54.
- Plasma volume a clue to abnormal test results. 87 April 76.

**Brief Summary:** ANAPROX® (naproxen sodium)

**Indications:** Relief of mild to moderate pain; treatment of primary dysmenorrhea.

**Contraindications:** Patients who have had allergic reactions to NAPROSYN or ANAPROX or whom aspirin or other NSAIDs induce the syndrome of asthma, rhinitis, and nasal polyps.

**Warnings:** GI bleeding, sometimes severe, and occasionally has been reported. Do not give to patients with active peptic ulcer unless potential benefit outweighs risk. Administer to those and others with history of GI disease only under close supervision.

**Precautions:** DO NOT GIVE NAPROSYN® (NAPROXEN) CONCOMITANTLY WITH ANAPROX® (NAPROXEN SODIUM) SINCE BOTH CIRCULATE IN PLASMA AS THE NAPROXEN ANION. Because anaphylactic reactions usually occur in patients with a history of reactions, question patients for asthma, nasal polyps, urticaria, and hypersensitivity associated with NSAIDs before starting therapy. It is recommended to discontinue the drug if anaphylactic nephritis with hematuria, proteinuria, and nephrotic syndrome has been reported. Patients with impaired renal function, heart failure, liver dysfunction, taking diuretics, and the elderly are at greater risk of overt renal decompensation. If this occurs, discontinue the drug. Use with caution and monitor serum creatinine and/or creatinine clearance in patients with significantly impaired renal function. Use caution in patients with baseline creatinine clearance less than 20 ml/minute. Use caution when high doses are required in the elderly or in patients with chronic alcoholic liver disease or cirrhosis. With NSAIDs, borderline elevations of liver tests may occur in up to 15% of patients. They may progress, remain unchanged, or be transient without clinical symptoms. Determinations of SGPT and SGOT occurred in controlled clinical trials in less than 1% of patients. Severe hepatic reactions, including jaundice and fatal hepatitis, have been reported. If liver disease develops or if systemic manifestations occur (e.g., eosinophilia or rash), discontinuous therapy. If steroid dose is reduced or eliminated during therapy, do so slowly and observe patients closely for adverse effects, including adrenal insufficiency and exacerbation of arthritis symptoms. Determining hemoglobin values frequently for patients with initial values of 10 grams or less who receive long-term therapy. Peripheral edema has been reported. For patients with restricted sodium intake, note that each tablet contains 140 mg of sodium. Use caution in patients with fluid retention, hypertension or heart failure. The drug's antipyretic and anti-inflammatory activities may reduce fever and inflammation, diminishing their diagnostic value. Conduct ophthalmic studies soon after starting therapy and at periodic intervals if the drug is used for an extended period.

**Information for Patients:** Patients should use caution for activities requiring alertness if they experience drowsiness, dizziness, vertigo or depression during therapy.

**Drug Interactions:** Use caution when giving concomitantly with coumarin-type anticoagulants, a hydantoin, sulfonamide or sulfonylurea; furosemide; lithium; beta-blockers, propranolol, or methotrexate.

**Drug Laboratory Test Interactions:** The drug may decrease lactate dehydrogenase and prolong bleeding time or increase urinary values for 17-ketogenic steroids. Temporarily stop therapy for 72 hours before doing adrenal function tests. The drug may interfere with urinary assays of SHIAA.

**Carcinogenesis:** A 2-year rat study showed no evidence of carcinogenicity.

**Pregnancy:** Category B. Do not use during pregnancy unless clearly needed. Avoid use during late pregnancy.

**Nursing Mothers:** Avoid use in nursing mothers.

**Pediatric Use:** Indications and dosage have not been established.

**Adverse Reactions:** Incidence Greater Than 1%: GI. The frequent complaints related to the GI tract, constipation, heartburn, abdominal pain,\* caused\* dyspepsia, diarrhea, stomatitis. CNS: headache\*, dizziness\*, drowsiness\*, light-headedness, vertigo. Dermatologic: itching (pruritis)\*, skin eruptions\*, ecchymoses\*, sweating, purpura. Special Senses: tinnitus\* hearing disturbances, visual disturbances. Cardiovascular: edema\*, dyspnea\*, palpitations. General: thirst. \*Incidence of reported reaction 3%-9%. Where unmarked, incidence less than 3%. Incidence Less Than 1%. Probable Causal Relationship: GI: abnormal liver function tests, GI bleeding and/or perforation, hematemesis, jaundice, melena, peptic ulceration with bleeding and/or perforation, vomiting. Renal: glomerular nephritis, interstitial nephritis, nephrotic syndrome, renal disease. Hematologic: eosinophilia, granulocytopenia, leukopenia, thrombocytopenia. CNS: depression, dream abnormalities, inability to concentrate, insomnia, malaise, myalgia and muscle weakness. Dermatologic: alopecia, photosensitive dermatitis, skin rashes. Special Senses: hearing impairment. Cardiovascular: congestive heart failure. Respiratory: eosinophilic pneumonitis. General: anaphylactoid reactions, menstrual disorders, pyrexia (chills and fever). Causal Relationship Unknown: Hematologic: agranulocytosis, aplastic anemia, hemolytic anemia. CNS: cognitive dysfunction, somnolence, epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome, urticaria. GI: ulcerative stomatitis. Cardiovascular: vasculitis. General: angioneurotic edema, hyperglycemia, hypoglycemia.

**Overdosage:** May have drowsiness, heartburn, indigestion, nausea, vomiting. Empty stomach and use usual supportive measures. Prompt administration of 5 grams activated charcoal may reduce drug absorption.

**Dosage and Administration for Mild to Moderate Pain, Dysmenorrhea and Acute Tendinitis and Bursitis:** The recommended starting dose is two 275 mg tablets, followed by one 275 mg tablet every 6 to 8 hours, as required. The total daily dose should not exceed 5 tablets (1375 mg).

**Caution:** Federal law prohibits dispensing without prescription.

**Set package insert for full Prescribing Information.**

© Revised 6/86

\*24



## Year-End Index

Guide to  
Major Subjects  
and Authors

Policing compliance. 87 April 108.  
Predictor for Colles' fracture reduction. 87 March 122.

Preventing allergy fatalities. 87 Feb 39.  
Procedure for examining synovial fluid. 87 Feb 39.

Prop patient for better ECG tracing. 87 Jan 129.  
Proper cathartic facilitates parasite studies. 87 March 154.

Providing a vent for subungual hematoma. 87 Jan 129.

Quick and easy fingertip hemostasis. 87 Sept 80.

Quick relief for low back pain. 87 Jan 31.  
Relief for fingertip splits. 87 Dec 82.

Relief for oral ulcers. 87 Aug 102.  
Removing an imbedded object from the nail. 87 Aug 84.

Ruling out hip fracture in an unresponsive patient. 87 June 148.

Savethe stitches. 87 Aug 58.

Secure the hand for stitching. 87 June 114.  
Simple screen for one cause of secondary hypercholesterolemia. 87 May 64.

Slap down injection discomfort. 87 March 154.

Sorting out valid narcotics requests. 87 May 64.

Speedy splinter removal. 87 Dec 82.  
Staples for repairing fragile skin. 87 April 108.

Swallowing sucralfate. 87 Dec 82.  
Tap to divine fluid in knee. 87 Jan 31.

Test for patency of salivary duct. 87 Sept 80.

Testing with confidence. 87 March 122.  
The Trichomonas tango. 87 Sept 80.

Tick trick. 87 June 80.

To warm a speculum. 87 Aug 102.  
Tobacco—get the message across. 87 Dec 82.

Traveling mammograms. 87 Oct 156.

Two-purpose tourniquet. 87 Jan 67.

Upright aspirin ingestion. 87 July 110.

Vanishing act for verrucae. 87 July 90.

Versatile, cost-effective office tool. 87 March 62.

What's in an eye? 87 Oct 54.

Worth a thousand words. 87 July 90.

Wound debridement made easy. 87 Oct 156.

Yellow secretions a clue to future events. 87 June 114.

**Pregnancy, ectopic, early diagnosis.**

Quartell A, Denehy T, Breen JL. 87 Oct 56.

**Pulmonary eosinophilia,** tracking the cause. Sharma OP, Nam H. 87 June 115.

**Puzzling Cases**

Abrupt worsening of chronic type B hepatitis (type A infection). Shorey J. 87 July 39.

An afebrile, semicomatosed young woman (myasthenia gravis). Amin NM. 87 March 56.

An unusual case of dyspnea and vomiting (esophageal rupture). Kessler MR. 87 Jan 124.

A patient with abdominal pain and hyperamylasemia (esophageal rupture). O'Shea JS. 87 Dec 75.

Dyspnea and rapid heart beat in a 50-year-old man (hyperthyroidism). Garvin JM. 87 Oct 44.

Recurring fever and rash in a young woman (adult Still's disease). Sack KE. 87 May 141.

Seven-year skin lesions (mycosis fungoïdes). Wooldridge WE. 87 Feb 119.

Sudden fever, rash, and unexplained hostility in a young GI (meningitis). Lichstein J. 87 April 54.

Two unrelated children with midline facial masses (dermoid cysts of the nose). Ladenheim SE, Grimes CD Jr. 87 Aug 118.

Why did this man keep falling down? (progressive supranuclear palsy). Lux WE, Kurtzke JF. 87 Aug 151.

Why the severe monomelic joint contractures and muscle paralysis? (conversion reaction). Dunn AW. 87 June 163.

**Questions Most Frequently Asked By Physicians, about...**

Acquired Immune Deficiency Syndrome. Volberding PA. 87 March 49.

arthroscopy of knee in osteoarthritis. Sequeira W, Arnold WJ. 87 Oct 25.

transient ischemic attacks. Paulson GW. 87 July 23.

**Radiology,** head and neck, for jaw and temporal bone disorders. Tirman RM. 87 Jan 88.

head and neck, for sinuses, salivary glands, larynx, facial fractures. Tirman RM. 87 July 49.

hepatobiliary imaging, advantages of newer techniques. Grant EG, White EM, Zeman RK. 87 March 30.

scintigraphy for benign skeletal disease. Lecklitner ML. 87 May 51.

**Respiratory function tests,** knowing which to use in asthma. Beer DJ. 87 July 29.

**Respiratory tract diseases**

exercise-induced asthma, testing and preventive measures. Owens GR. 87 March 23.

pulmonary eosinophilia, tracking the cause. Sharma OM, Nam H. 87 June 115.

**Seizures,** history and physical more discerning than high tech. Bergia B, Epstein CM. 87 June 103.

**Sexual dysfunction, male, office management (Part 2).** Melman A. 87 Jan 56.

**Sigmoidoscopy,** care and maintenance of flexible scopes. Abcarian H. 87 April 51.

logistics and economics of office use. Varma JR. 87 Aug 96.

**Skin diseases, psoriasis, management.** Hall JC. 87 Dec 67.

**Stomach neoplasms,** Japanese experience in treatment options. Douglass HO Jr. 87 Feb 75.

**Substance dependence,** alcohol and drugs, how to spot and what steps to take. Chappel JN. 87 April 60.

**Surgery,** noncardiac, for cardiac patients. Silver MD, Cheitlin MD. 87 Oct 139.

**Thyroid gland,** changes with aging and clinical implications. Felicetta JV. 87 Sept 71.

**Trigeminal neuralgia,** treatment options. Goodkin R. 87 Feb 51.

**United States Health Care Financing Administration,** agenda for Medicare in the future. Roper WL. 87 Sept 94.

**Urinary incontinence,** in women, tips on diagnosis and treatment. Shull BL. 87 March 147.

**Vaccines,** unpredictable neurologic syndromes. Poser CM. 87 Jan 45.

**Vasectomy,** safety and technique. Blauth RA. 87 Feb 97.



- AUTHORS:**
- Abcarian, Herand** care and maintenance of flexible sigmoidoscopes, 87 April 51.
  - Abrams, Jonathan** indications for nitrate therapy (Part 1), 87 June 154; guidelines for various delivery systems (Part 2), 87 July 100.
  - Adams, George J.** evaluation of midfacial fractures, 87 Oct 101.
  - Alberts, Michael S.** pros and cons of starting a specialized clinic (CCC), 87 Oct 83.
  - Alberts, Phillip S.** pros and cons of starting a specialized clinic (CCC), 87 Oct 83.
  - Alberts, Suzanne L.** pros and cons of starting a specialized clinic (CCC), 87 Oct 83.
  - Amin, Navin M.** myasthenia gravis (Puzz Case), 87 March 56; update on the cephalosporins, 87 June 25.
  - Anderson, James W.** nutritional therapy for NIDDM, 87 May 40.
  - Andriole, Dorothy P.** intra-abdominal complications of AIDS (Part 1), 87 Jan 106; treatment and staff protection (Part 2), 87 Feb 145.
  - Arnold, William J.** arthroscopy for osteoarthritis of the knee (Phys Questions), 87 Oct 25.
  - Barenholz, Lawrence** obvious and hidden tradeoffs in leaving private practice for prepay plan (CCC), 87 March 85.
  - Beaton, James H.** taking action on abnormal pap smears (Brf Consult), 87 April 133.
  - Beer, Dennis J.** which pulmonary function tests to use in asthma, 87 July 29.
  - Berenson, Robert A.** financial risks and ethical dilemmas of capitation in IPA-HMOs (CCC), 87 Sept 190.
  - Berger, Peter** diagnostic criteria for primary mitral valve prolapse, 87 Sept 114.
  - Bergia, Berta** clinical diagnosis of seizures and blackouts, 87 June 103.
  - Bicknell, Joseph M.** restless leg syndrome (Brf Consult), 87 Nov 117.
  - Black, Henry R.** integrating old and new in antihypertensive therapy (Article Comm), 87 April 3; look out America! Here comes cholesterol! (Article Comm), 87 Dec 3.
  - Blath, Richard A.** vasectomy, 87 Feb 97.
  - Blitzer, Andrew** complications of paranasal sinus infections, 87 Feb 131.
  - Blodi, FC** possible candidate for radical keratotomy (Brf Consult), 87 March 40.
  - Bolt, Robert J.** chemical dissolution for gallstones, 87 Sept 129.
  - Breen, James L.** ectopic pregnancy, 87 Oct 56.
  - Broderick, Thomas W.** outpatient percutaneous biopsy guided by CT, 87 June 142.
  - Buenafior, Michael** countering HMO marketing practices (CCC), 87 June 92.
  - Buseck, Mark** six mechanisms of acute ankle trauma, 87 Aug 130.
  - Campbell, Bruce F.** contraception counseling update, 87 Nov 23.
  - Carbone, Paul P.** options for high-risk breast cancer (Brf Consult), 87 Jan 41.
  - Chan, Juli A.** preventing viral contamination of blood supplies, 87 Oct 121.
  - Chappel, John N.** spotting and managing alcoholism and other drug dependencies, 87 April 60.
  - Cheitlin, Melvin D.** preoperative evaluation of cardiac patients for noncardiac surgery, 87 Oct 139.
  - Cherner, Rachmel** antihypertensive agents and diabetes, 87 Feb 22.
  - Collins, Michael F.** young physicians: factors that shape their professional lives (CCC), 87 Nov 86.
  - Cone, JB** outpatient management of minor burns, 87 Oct 37.
  - Connolly, John F.** awkward young athlete (Brf Consult), 87 Feb 115.
  - Cook, Steven P.** On call (Mem Moment) 87 Jan 166.
  - Cressman, Michael D.** antihypertensive agents: new diuretics,  $\beta$ -blockers, sympatholytics (Part 1), 87 April 29; calcium channel blockers and ACE inhibitors (Part 2), 87 May 28; niacin therapy for hyperlipoproteinemia (Brf Consult), 87 Nov 57.
  - Curran, David L.** contraception counseling update, 87 Nov 23.
  - Davis, Richard B.** selection and interpretation of lab tests for bleeding disorders, 87 May 111.
  - Denehy, Thad** ectopic pregnancy, 87 Oct 56.
  - Douglass, Harold O.** Japanese experience with gastric cancer, 87 Feb 75.
  - D'Silva, Joseph** six mechanisms of acute ankle trauma, 87 Aug 130.
  - Dunn, A. William** conversion reaction (Puzz Case), 87 June 163.
  - DuPont, Herbert L.** strategies to decrease risk of travelers' diarrhea, 87 May 102.
  - Engel, Stephen** saving the spleen (Brf Consult), 87 March 127.
  - Epstein, Charles M.** clinical diagnosis of seizures and blackouts, 87 June 103.
  - Ericsson, Charles D.** strategies to decrease risk of travelers' diarrhea, 87 May 102.
  - Ermann, Dan** preferred provider organizations (CCC), 87 April 102.
  - Farrar, John T.** upper GI endoscopy (Article Comm), 87 May 3.
  - Featherston, William E.** secondary causes of hypertension, 87 Aug 109.
  - Feig, Stephen A.** mammography—risk defined, accreditation on the way (Brf Consult), 87 May 85.
  - Felicetta, James V.** aging thyroid and its clinical effects, 87 Sept 71.
  - Fischer, Lee A.** the Palm Beach County Medical Society's response to HMO encroachment (CCC), 87 March 95.
  - Fitzgerald, Faith T.** flexible fiberoptic sigmoidoscopy (Article Comm), 87 Aug 3; looking for diagnostic clues from unconventional sources, 87 Sept 49.
  - Gabow, Patricia A.** using the anion gap measurement clinically, 87 April 119.
  - Gantz, Nelson** unconventional causes of pharyngitis, 87 Jan 159.
  - Gartner, J. Carlton Jr.** recurrent abdominal pain in children, 87 Oct 152.
  - Garvin, John M.** hyperthyroidism (Puzz Case), 87 Oct 44.
  - Gates, William H.** recognizing your own grief reaction to practice changes (CCC), 87 Aug 88.
  - Gifford, Ray W. Jr.** antihypertensive agents: new diuretics,  $\beta$ -blockers, sympatholytics (Part 1), 87 April 29; calcium channel blockers and ACE inhibitors (Part 2), 87 May 28.
  - Gillick, Muriel R.** Medicare HMOs, the new kid on the block (CCC), 87 Dec 97.
  - Gleckman, Richard A.** unconventional causes of pharyngitis, 87 Jan 159.
  - Gleeson, Frank G.** emergency medicine (Mem Moment) 87 Feb 96.
  - Goldberg, B. Abbott** don't be intimidated by third-party payor decisions (CCC), 87 May 81; AIDS and patient confidentiality (CCC), 87 Oct 70.
  - Goodkin, Robert** trigeminal neuralgia, 87 Feb 51.
  - Goodman, Robert P.** distinguishing between apparent and true resistant hypertension, 87 Sept 65.
  - Gotto, Antonio M. Jr.** hyperlipoproteinemia: risk assessment and dietary management (Part 1), 87 Nov 126; recommendations for cholesterol-lowering drugs (Part 2), 87 Dec 31.
  - Gouge, Thomas H.** intra-abdominal complications of AIDS (Part 1), 87 Jan 106; treatment and staff protection (Part 2), 87 Feb 145.
  - Grant, Edward G.** hepatobiliary imaging with newer techniques, 87 March 30.
  - Grimes, Cecil D. Jr.** dermoid cysts of the nose (Puzz Case), 87 Aug 118.
  - Gustafson, Nancy J.** nutritional therapy for NIDDM, 87 May 40.
  - Hall, John C.** psoriasis, improving control, 87 Dec 67.
  - Harrison, Christopher J.** tympanostomy tubes (Brf Consult), 87 March 143.
  - Hazzard, William R.** nutritional needs, glucose intolerance in the elderly (Brf Consult), 87 Nov 81.
  - Heller, Michael B.** mammalian bites, 87 Feb 40; local injection therapy for tendinitis/bursitis syndrome, 87 Dec 107.
  - Holverson, Harmon E.** the dilemma of therapeutic substitution (Ed Op), 87 June 166.
  - Hoogwerf, Byron J.** niacin therapy for hyperlipoproteinemia (Brf Consult), 87 Nov 57.
  - Horn, Susan D.** physician profiling, how it can be misleading (CCC), 87 Dec 86.
  - Hunder, Gene G.** systemic aspects of rheumatoid arthritis, 87 Nov 151.
  - Johnson, Philip C.** strategies to decrease risk of travelers' diarrhea, 87 May 102.
  - Jones, Peter H.** hyperlipoproteinemia: risk assessment and dietary management (Part 1), 87 Nov 126; recommendations for cholesterol-lowering drugs (Part 2), 87 Dec 31.
  - Kasik, JE** treatment of chronic airflow obstruction, 87 Nov 37.
  - Kemink, John L.** early office evaluation of hearing loss, 87 April 39.
  - Kessler, Michael R.** esophageal rupture (Puzz Case), 87 Jan 124.
  - Klein, Howard W.** conservative therapy for decubitus ulcers, 87 June 133.
  - Klish, William J.** pediatric gastroenteritis, 87 Sept 127.
  - Koch, Milton J.** peptic ulcer disease, 87 May 21.
  - Kohse, Larry M.** niacin therapy for hyperlipoproteinemia (Brf Consult), 87 Nov 57.
  - Kpea, Nomate T.** nail abnormalities as a sign of systemic disease, 87 Aug 47.
  - Kroger, J. Stephen** gauging appropriateness of office laboratory for your practice (CCC), 87 May 70; selecting office laboratory equipment and doing cost analysis (CCC), 87 July 71.
  - Krosnick, Arthur** switching IDDM patients to human insulin from other sources, 87 July 78.
  - Kurtzke, John F.** progressive supranuclear palsy (Puzz Case), 87 Aug 151.
  - Lachance, Paul A.** make use of a valuable resource—the nutritionist (Brf Consult), 87 July 113.

## Year-End Index

Guide to  
Major Subjects  
and Authors

**Ladenheim, Steven E** dermoid cysts of the nose (Puzz Case), 87 Aug 118.  
**Lange, Thomas A** evaluation of soft-tissue tumors in the extremities, 87 Nov 62.  
**Lecklitner, Myron L** scintigraphy for benign skeletal disease, 87 May 51.  
**Lerner, Robert G** high hemoglobin levels—risk for stroke? (Brf Consult), 87 May 39.  
**Levy, Robert I** pros and cons of fish oil (Brf Consult), 87 Sept 56.  
**Lichstein, Jacob** meningitis (Puzz Case), 87 April 54.  
**Lux, Warren E** progressive supranuclear palsy (Puzz Case), 87 Aug 151.  
**Mahoney, Donald H Jr** blood component therapy for children, 87 Jan 130.  
**McConnell, Richard Y** insect bites and tetanus—when prophylaxis is necessary, 87 Oct 43.  
**Meissner, Mark D** oral therapy for ventricular arrhythmias, 87 Jan 32.  
**Melman, Arnold** treating male sexual dysfunction, 87 Jan 56.  
**Morganroth, Joel** oral therapy for ventricular arrhythmias, 87 Jan 32.  
**Murphy, Dale P** too much dogma, not enough science (Article Comm), 87 July 3; AIDS: pray for reason (Article Comm), 87 Oct 3.  
**Myers, Frank W** contraceptive counseling: helping patients keep the facts straight (Article Comm), 87 Nov 3.  
**Nam, Helen** pulmonary eosinophilia, 87 June 115.  
**Nash, David B** physician-executive: emerging subspecialty for younger physicians (CCC), 87 Nov 97.  
**Newton, Michael** taking action on abnormal pap smears (Brf Consult), 87 April 133.  
**Niparko, John K** early office evaluation of hearing loss, 87 April 39.  
**Northrop, Gretajo** lower testosterone levels in male distance-runners, 87 Jan 147.  
**O'Connell, John B** inflammatory dilated cardiomyopathy, 87 May 146.  
**Olson, Donald R** how not to lose private patients over employer biases (CCC), 87 May 75.  
**O'Shea, John S** esophageal rupture (Puzz Case), 87 Dec 75.  
**Owens, Gregory R** testing methods and preventive measures for exercise-induced asthma, 87 March 23.  
**Parker, Brent M** identifying diagnostic pitfalls in electrocardiography, 87 Aug 34.  
**Paulson, George W** transient ischemic attacks (Phys Questions), 87 July 23.  
**Payson, Norman C** physician-controlled HMOs (CCC), 87 July 64.  
**Peppercorn, Mark A** diagnosis and management of acute gastrointestinal bleeding, 87 June 61.

**Petty, Thomas L** advanced lung disease, home oxygen therapy, 87 Dec 53.  
**Plante, Mary C** intra-abdominal complications of AIDS (Part 1), 87 Jan 106; treatment and staff protection (Part 2), 87 Feb 145.  
**Plehn, Jonathan F** diagnostic criteria for primary mitral valve prolapse, 87 Sept 114.  
**Podolsky, Gilbert** fee-for-service HMOs (CCC), 87 April 97.  
**Poser, Charles M** neurologic complications of vaccines and infections, 87 Jan 45.  
**Powe, Neil R** 'gatekeeper' role for primary care physician (CCC), 87 June 86.  
**Prichard, John G** choosing among the cephalosporins (Article Comm), 87 June 3.  
**Puschett, Jules B** selecting right diuretic for edematous patient, 87 May 125.  
**Quartell, Anthony** ectopic pregnancy, 87 Oct 56.  
**Rakel, Robert E** choosing among the cephalosporins (Article Comm), 87 June 3.  
**Raffel, Leslie J** common misconceptions in diabetes counseling, 87 Jan 23.  
**Ram, C Venkata S** secondary causes of hypertension, 87 Aug 109.  
**Raskind, Robert** unilateral eyelid twitch (Brf Consult), 87 May 58.  
**Ravdin, Peter M** options for high-risk breast cancer (Brf Consult), 87 Jan 41.  
**Redman, Jack C** γ-globulin and herpes (Brf Consult), 87 June 40.  
**Reynolds, Herbert Y** unusual presentations of asthma, 87 Sept 29.  
**Rimoin, David L** common misconceptions in diabetes counseling, 87 Jan 23.  
**Roper, William L** HCFA's new agenda for Medicare (CCC), 87 Sept 94.  
**Rosch, Paul J** workplace programs for managing stress (Brf Consult), 87 March 110.  
**Rozance, Christine** flexible fiberoptic sigmoidoscopy (Article Comm), 87 Aug 3.  
**Sack, Kenneth E** adult Still's disease (Puzz Case), 87 May 141.  
**Scher, Richard K** nail abnormalities as a sign of systemic disease, 87 Aug 47.  
**Schroeder, Steven A** medical costs crisis (Part 1; CCC), 87 March 68; medical costs crisis, regaining control (Part 2; CCC) 87 April 82.  
**Sequeira, Winston** arthroscopy for osteoarthritis of the knee (Phys Questions), 87 Oct 25.  
**Shahady, Edward J** promising therapy for migraine headache (Article Comm), 87 Jan 3; Marketing your practice ethically (CCC), 87 March 90; considering the atypical asthmatic patient (Article Comm), 87 Sept 3.  
**Shapiro, David B** β-blockers for migraine prophylaxis, 87 Jan 117.

**Sharma, Om P** pulmonary eosinophilia, 87 June 115.  
**Shorey, James** hepatitis A infection (Puzz Case), 87 July 39.  
**Shull, Bobby L** diagnosis and management of urinary incontinence in women, 87 March 147.  
**Silver, Mitchell D** preoperative evaluation of cardiac patients for noncardiac surgery, 87 Oct 139.  
**Sloan, Richard W** antiulcer treatment in the elderly, 87 Aug 59.  
**South-Paul, Jeannette E** exercise for the elderly, 87 Feb 63.  
**Speir, William A** inhaled β<sub>2</sub>-bronchodilators as first-line therapy for reversible airway obstruction, 87 April 134.  
**Stepleton, F Bruder** hypercalcemia and hematuria in children, 87 Aug 73.  
**Swanson, David A** self-examination for testicular cancer, 87 April 142.  
**Taylor, C Barr** post-MI management to avert psychological problems, 87 June 45.  
**Taylor, Robert A** inhaled β<sub>2</sub>-bronchodilators as first-line therapy for reversible airways obstruction, 87 April 134.  
**Thomas, H Emerson Jr** indications for hyperlipidemia therapy (Brf Consult), 87 Jan 82.  
**Tirman, Robert M** radiologic evaluation of jaw and temporal bone disorders, 87 Jan 88; radiologic evaluation of sinuses, salivary glands, larynx, facial fractures, 87 July 49.  
**Turner, Ransom B** gate guardian: a role for the FP to resume? (Ed Op), 87 Oct 92.  
**Varma, JR** logistics and economics of flexible sigmoidoscopy in the office, 87 Aug 96.  
**Vidt, Donald G** β-blockers for cardiac conditions and hypertension, 87 March 128.  
**Volberding, Paul A** acquired immune deficiency syndrome (Phys Questions), 87 March 49.  
**Vyas, Girish N** preventing viral contamination of blood supplies, 87 Oct 121.  
**Walter, Robert M** JF therapy for osteoporosis, 87 March 115.  
**White, E Maureen** hepatobiliary imaging with newer techniques, 87 March 30.  
**Williams, H James** toxicity of low-dose pulse methotrexate in the treatment of rheumatoid arthritis (Brf Consult), 87 June 151.  
**Wolin, Preston M** six mechanisms of acute ankle trauma, 87 Aug 130.  
**Wooldridge, Wilfred E** mycosis fungoidea (Puzz Case), 87 Feb 119.  
**Zeman, Robert K** hepatobiliary imaging with newer techniques, 87 March 30.

